<DOC>
	<DOCNO>NCT00460746</DOCNO>
	<brief_summary>The purpose study examine safety , tolerability , effectiveness darunavir/ritonavir combine TMC125 current protease inhibitor ( ) , Non-Nucleoside Reverse Transcriptase Inhibitors ( NNRTI ( ) ) enfuvirtide replace darunavir/ritonavir TMC125 HIV positive patient longer tolerate enfuvirtide experience viral suppression . Other antiviral drug regimen remain unchanged .</brief_summary>
	<brief_title>Enfuvirtide/Current Protease Inhibitor Switch PREZISTA ( Darunavir ) /Ritonavir + TMC125 HIV Patients With Enfuvirtide Side Effects .</brief_title>
	<detailed_description>This multi-center , open-label ( doctor patient know drug give ) , Phase IIIb clinical trial evaluate effectiveness , safety tolerability combination PREZISTA ( darunavir ) /ritonavir TMC125 substitute enfuvirtide , current protease inhibitor ( ) Non-Nucleoside Reverse Transcriptase Inhibitors ( NNRTI ( ) ) antiretroviral resistant patient viral suppression intolerant enfuvirtide . This study conduct U.S. 5 site 40 patient receive PREZISTA ( darunavir ) /ritonavir twice daily ( 600/100mg ) TMC125 ( 200 mg ) twice daily 48-week treatment period . The study consist total 11 patient visit . At screen visit ( Week -1 -6 ) blood collect patient determine eligibility . Once data available determine eligibility patient , baseline visit schedule trial treatment initiated visit . The Baseline Visit ( Day 1 ) follow 48-week treatment period . The patient evaluate Weeks 2 , 4 , 8 , 12 , 16 , 24 , 36 , 48 . Patients ask return 2-week follow visit Week 50 . Treatment include PREZISTA ( darunavir ) /ritonavir TMC125 plus continued nucleoside . The patient must continue exist nucleoside background regimen duration study . During treatment period , patient see regular visit investigator assess patient 's medical condition , Adverse Events study drug compliance . Laboratory evaluation efficacy safety do regular visit . Study patient receive oral ( mouth ) PREZISTA ( darunavir ) 600 mg 100 mg ritonavir twice day combination TMC125 200mg orally twice day 48 week .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Documented HIV1 positive History drug resistance antiretroviral failure receive three drug class : Nucleoside Reverse Transcriptase Inhibitors ( NRTIs ) , NonNucleoside Reverse Transcriptase Inhibitors ( NNRTIs ) ( protease inhibitor ) PIs On PI contain regimen enfuvirtide HIV viral load ( VL ) &lt; 400 copies/mL 6 month longer Continuously use PI regimen 4 month prior Screening Decline continue enfuvirtide physician recommend discontinuation due injection site reaction persist despite optimal technique training available method administration loss sit injection due tissue nodule harden . No use drug contraindicate current US package insert PREZISTA ( darunavir ) investigator brochure TMC125 No prior current therapy PREZISTA ( darunavir ) TMC125 No prior genotypic result demonstrate 3 darunavir resistanceassociated mutation associate diminished response darunavir ( V11I , V32I , L33F , I47V , I50V , I54L , I54M , G73S , L76V , I84V L89V ) . Patients &gt; 3 darunavir resistanceassociated mutation available darunavir phenotype , may enrol resistance phenotype demonstrate : Fold Change ( FC ) &lt; 10 darunavir PhenoSense GT ( Monogram Biosciences ) FC &lt; 10 darunavir Antivirogram ( Virco , BVBA ) FC &lt; 3.4 darunavir vircoTYPE ( Virco BVBA ) AST ALT &gt; 5 time ULN Calculated CrCl &lt; 30 ml/min .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>Immunodeficiency Virus , Human</keyword>
	<keyword>PREZISTA</keyword>
	<keyword>darunavir</keyword>
	<keyword>TMC114</keyword>
	<keyword>TMC125</keyword>
	<keyword>Protease Inhibitor</keyword>
	<keyword>Non-Nucleoside Reverse Transcriptase Inhibitor</keyword>
	<keyword>enfuvirtide</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>